Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial – CNBC
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial CNBCLilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes Eli Lilly‘Godzilla’ of weight-loss drugs could provide other important health benefits The GuardianLilly's experimental drug cuts weight by 21% in diabetes trial ReutersMost powerful obesity drug yet: People lost up to 25% of weight in trial Ars Technica
সূত্র: মূল সংবাদসূত্র